Group 1 - The A-share pharmaceutical sector has rebounded, with medical device stocks and AI healthcare concepts leading the gains, including significant increases in companies like Meinian Health and Lepu Medical [1][8] - The largest medical ETF in the market (512170) saw a nearly 1% increase, with a net subscription of 77.77 million yuan the previous day [1][8] - A new policy from the Beijing-Tianjin-Hebei region is expected to benefit CXO and medical device companies by improving clinical trial efficiency and reducing compliance costs [2][5][10] Group 2 - The FDA has announced a new default standard for drug approvals, allowing for a single key clinical trial plus confirmatory evidence, which is projected to shorten development cycles and reduce capital costs significantly [4][12] - The cost of a single key trial is estimated to range from 30 million to 150 million USD, which will enhance the research efficiency of innovative drug companies [4][12] - The medical ETF (512170) has over 50% weight in medical devices and more than 25% in CXO, covering 12 AI medical and brain-computer interface concept stocks [4][12] Group 3 - The pharmaceutical sector is stabilizing, with mixed performance among innovative drug concepts; companies like Sanofi and Dizhiyuan have shown notable fluctuations [2][10] - Traditional Chinese medicine stocks have generally risen, with companies like Darentang and Jilin Aodong seeing increases of over 2% [2][10] - The only ETF tracking the pharmaceutical index (562050) turned positive during trading, indicating a recovery in the sector [2][10]

Core Viewpoint - The pharmaceutical retail market is transitioning towards high-quality development, with significant growth opportunities anticipated in various segments, including traditional Chinese medicine, medical devices, and innovative drugs [17][22][46]. Market Overview - The retail scale of China's physical pharmacies for January to November 2025 is projected to reach 557.7 billion yuan, showing a slight year-on-year decline of 0.8%. However, the cumulative scale for October and November is expected to be 108.7 billion yuan, reflecting a year-on-year growth of 4.0% [22][30]. - The pharmaceutical retail market is experiencing a recovery phase, driven by ongoing healthcare reforms and the optimization of market structures, which are expected to enhance the industry's long-term growth prospects [22][30]. Category Analysis - **Pharmaceuticals**: The cumulative scale for pharmaceuticals from January to November 2025 is estimated at 453.4 billion yuan, with a year-on-year growth of 0.4%. The sales scale for October and November is projected to be 88 billion yuan, with a year-on-year increase of 5.5% [29]. - **Traditional Chinese Medicine (TCM)**: The cumulative scale for TCM from January to November 2025 is expected to be 42.9 billion yuan, reflecting a year-on-year decline of 4.2%. However, November shows a month-on-month growth of 12.5% [30]. - **Medical Devices**: The cumulative scale for medical devices is projected to be 26.1 billion yuan, with a slight year-on-year decline of 0.4%. The sales scale for October and November is expected to show a year-on-year growth of 6.3% [37]. - **Health Products**: The cumulative scale for health products is anticipated to be 21 billion yuan, with a year-on-year decline of 15.7%. However, November shows signs of recovery with a month-on-month growth of 5.3% [34]. Investment Opportunities - The pharmaceutical sector is expected to benefit from a low valuation environment, with public funds showing low allocation to the sector. The anticipated recovery in macroeconomic factors and the demand for major products are expected to drive growth in the industry [15]. - The innovative drug sector is transitioning from quantity to quality, with a focus on differentiated products and internationalization. Companies with strong pipelines and the ability to deliver profits are recommended for investment [15][46]. - The medical device market is witnessing a recovery in bidding volumes, with ongoing updates and international expansion opportunities. Companies focusing on innovation and product upgrades are expected to perform well [46]. Specific Product Trends - **Top Chemical Drugs**: In October and November 2025, the top 20 chemical drug categories accounted for 78.3% and 80.0% of the market share, respectively, with significant growth in categories such as anti-tumor drugs and systemic antiviral drugs [40][41]. - **Top Traditional Chinese Medicine Products**: The market share for TCM in November reached 86.4%, with notable growth in cold medications and cough remedies [44][45]. Conclusion - The pharmaceutical retail market is poised for a significant transformation, with various segments showing potential for growth. The ongoing reforms and market dynamics are expected to create a favorable environment for investment in the pharmaceutical and healthcare sectors [22][30][46].

下跌方面，大消费板块集体下挫，白酒、旅游酒店方向跌幅居前，皇台酒业跌停，大连圣亚触及跌停。截至收盘，沪指涨0.11%，深成指涨 0.65%，创业板指涨0.65%。 下载财联社APP获取更多资讯 准确 快速 权威 专业 7x24h电报 头条新闻 VIP资讯 实时盯盘 今日早盘，A股市场探底回升，三大指数集体翻红，此前一度跌超1%。沪深两市半日成交额1.38万亿，较上个交易日缩量633亿。盘面上热点快速轮 动，全市场超3800只个股上涨。 从板块来看， 化工板块集体走强， 沧州大化、金牛化工、百川股份、百合花涨停。人形机器人概念表现活跃，五洲新春、联诚精密、天奇 股份涨停。 有色金属板块回暖， 湖南黄金、翔鹭钨业涨停。光通信概念震荡回升，杭电股份6天5板。中药概念开盘活跃，特一药业涨停。 ...

两市成交额:1.38万亿 较上一日:-633亿 今日预测量能: 2.12万亿 -566亿 | | | | | 沪深京重要指数 | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | *● 名称 | 最新 | 涨幅% | | 涨跌 | 涨速% | 总手 | 现手 金额 | | 上证指数 | 4080.31 | 0.11 | 4.39 | 1506/747 | 0.12 | 3.55 Z | 3.57万 5767.46亿 | | 深证成指 | 14043.17 | 0.65 | 90.46 | 2113/716 | 0.22 | 4.78 7. | 1029 8074.52亿 | | 北证50 | 1523.13 | 1.05 | 15.84 | 261/25 | 0.16 | 4597 | 139 108.47 7. | | 创业板指 | 3281.45 | 0.65 | 21.17 | 1062/305 | 0.31 | 1.4017 | 1029 3605.39亿 | 盘面上热点快速轮动，全市场超3800只个股上涨。从板块来看，化工板块集体走强 ...

转自：智通财经 【午评：创业板指半日涨0.65% 化工板块集体走强】智通财经2月6日电，市场早盘探底回升，三大指数 集体翻红，此前一度跌超1%。沪深两市半日成交额1.38万亿，较上个交易日缩量633亿。盘面上热点快 速轮动，全市场超3800只个股上涨。从板块来看，化工板块集体走强，沧州大化、金牛化工、百川股 份、百合花涨停。人形机器人概念表现活跃，五洲新春、联诚精密、天奇股份涨停。有色金属板块回 暖，湖南黄金、翔鹭钨业涨停。光通信概念震荡回升，杭电股份6天5板。中药概念开盘活跃，特一药业 涨停。下跌方面，大消费板块集体下挫，白酒、旅游酒店方向跌幅居前，皇台酒业跌停，大连圣亚触及 跌停。截至收盘，沪指涨0.11%，深成指涨0.65%，创业板指涨0.65%。 ...

每经记者｜黄胜 每经编辑｜金冥羽 记者|黄胜 编辑|金冥羽 杜波 校对|许绍航 2月6日，三大指数探底回升全线翻红，创业板指早盘一度跌近2%。超4000只个股上涨，锂电、中药、化工、电网、油气等方向涨幅居前。 | Wind热门概念指数 | | | | | --- | --- | --- | --- | | 伊电电 化学纤 磷化工 氟化工 化学原 维生素 特高压 细矿 | | | 动力电 | | 5.38% 3.70% 3.43% 3.16% 3.12% 2.94% 2.86% 2.78% 2.76% | | | | | 伊电正 | 钢离子 固态电 锂电池 钾电负 铝产业 PEEK材 小金属 磷酸铁 | | | | 2.71% 2.58% 2.57% 2.54% 2.52% 2.45% 2.45% 2.42% 2.44% | | | | | 黄金珠 化学制 光通信 字树机 电池回 宁德时 西藏振 开线充 | | | 中级 | | 2.38% 2.35% 2.24% 2.26% 2.19% 2.18% 2.14% 2.14% | | | 2.09% | | 储能 稀有金 高速铜 航运 首发经 腾讯平 Kimi | ...

Group 1 - A-shares opened lower and experienced significant adjustments, while the pharmaceutical sector showed resilience by performing well in the market [1] - The National Medical Products Administration announced on February 4 that during the 14th Five-Year Plan period, there will be strong support for the innovation and development of the biomanufacturing industry, transitioning the pharmaceutical industry from "follow-up innovation" to "systematic innovation" [1][3] - Analysts are optimistic about the Chinese medicine sector, expecting valuation recovery and performance improvement driven by policy support, cost improvements, and adjustments to the essential drug catalog [3] Group 2 - The raw material drug sector is viewed positively, with expectations of price recovery after several years of price declines, supported by rising prices of bulk commodities and upstream chemicals [3] - The medical ETF, the largest in the market, had a scale of 27.5 billion yuan as of February 3, 2026, indicating strong investor interest [3] - The pharmaceutical sector showed mixed performance, with innovative drug concepts mostly declining, while traditional Chinese medicine leaders like Darentang and Pizaihuang saw significant gains [5]

Group 1 - The A-share market opened lower and experienced significant adjustments, while the healthcare sector showed resilience with major stocks like WuXi AppTec rising over 1% and Aier Eye Hospital increasing by over 2% [1] - The largest healthcare ETF (512170) has seen a net subscription of 2.688 billion yuan over the past 13 days, indicating strong investor interest [1] - The pharmaceutical sector showed mixed performance, with innovative drug concepts mostly declining, while traditional Chinese medicine stocks like Darentang rose over 4% [3] Group 2 - The National Medical Products Administration announced support for the biomanufacturing industry during the 14th Five-Year Plan, aiming to shift the pharmaceutical industry towards systematic innovation and quality growth [5] - Analysts are optimistic about the Chinese medicine sector's recovery driven by policy support, cost improvements, and expected adjustments in the essential drug catalog [5] - Zhongtai Securities is bullish on the raw material drug sector, anticipating price improvements after several years of price declines, with most API product prices at historical lows [5] Group 3 - The largest healthcare ETF (512170) has over 50% weight in medical devices and more than 25% in CXO, covering 12 AI medical and brain-computer interface concept stocks [5] - The only pharmaceutical ETF (562050) has over 60% allocation in innovative drugs while also considering high-dividend Chinese medicine stocks [5] - As of February 3, 2026, the healthcare ETF has a total scale of 27.5 billion yuan, making it the largest in the market [6]

行 业 研 究 / 医 药 生 物 / 证 券 研 究 报 医药生物行业周报 《药品管理法实施条例》全面修订，推 动医药产业创新与监管升级 2026 年 02 月 03 日 【行情回顾】 【本周观点】 【风险提示】 医药行业政策风险；研发进展不及预期风险；业绩不及预期风险 挖掘价值 投资成长 强于大市（维持） 东方财富证券研究所 证券分析师：何玮 证书编号：S1160517110001 证券分析师：崔晓倩 《医药零售高质量发展政策发布，行业有 望加速整合利好龙头》 2026.01.27 《J.P. Morgan 健康大会召开，中国创新药 企扬帆出海》 2026.01.20 《聚焦脑机接口与小核酸药物，JPM 盛会 前奏下医疗布局新浪潮》 2026.01.14 《创新浪潮涌动下，医药板块修复与突破 之路》 证书编号：S1160525080001 相对指数表现 -10% 0% 10% 20% 30% 40% 2025/2 2025/8 2026/2 医药生物 沪深300 相关研究 2025.12.15 《医药生物行业 2025 年三季报财报总结： 业绩分化，医疗设备板块显现拐点》 2025.11.13 告 本周( ...

发布时间：2026-02-02 行业投资评级 强于大市|维持 | 行业基本情况 | | | --- | --- | | 收盘点位 | 8338.3 | | 52 周最高 | 9323.49 | | 52 周最低 | 6876.88 | 行业相对指数表现 -5% -1% 3% 7% 11% 15% 19% 23% 27% 31% 2025-02 2025-04 2025-06 2025-09 2025-11 2026-01 医药生物 沪深300 资料来源：聚源，中邮证券研究所 研究所 分析师:盛丽华 SAC 登记编号:S1340525060001 Email:shenglihua@cnpsec.com 分析师:徐智敏 SAC 登记编号:S1340525100003 Email: xuzhimin@cnpsec.com 近期研究报告 2025 年有数十个 AI 衍生的管线进入人体临床试验，但回顾过往 管线来看，与任何其他新技术的发展一样，AI 制药的发展之路也是曲 折的。AI 制药极大加速了临床早期的进程同时亦能取得超出传统经验 水平的 1 期成功率（80%~90% vs 40%~65%），而在 2 期及后续的进 ...